On Jan. 5, 2026, Novo Nordisk announced that the Wegovy^® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity.

Wegovy^® pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.

Wegovy^® is backed by proven results, as millions have been prescribed Wegovy^® (semaglutide) injection 2.4 mg for weight management since 2021. Wegovy^® pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials, boasting an average weight loss of about 17% (16.6%), when used along with a reduced calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo. When looking at the efficacy regardless of if all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy^® pill compared to about 2% (2.4%) for placebo.

With once-daily oral dosing, Wegovy^® pill can provide patients with a practical option as part of their daily routine to help people achieve meaningful weight loss.  For Wegovy^® pill based on baseline body weight of 235 lb., and for placebo based on baseline body weight of 231 lb. In OASIS 4, common adverse reactions were similar to those previously seen in clinical trials with Wegovy^® (semaglutide) injection 2.4 mg, including nausea, diarrhea, and vomiting.

Wegovy^® pill is available to all eligible patients with multiple affordability options. Self-pay patients can start at around $5/day ($149/month) for the starting dose of 1.5 mg. The 4 mg dose will also be available for $149/month through April 15, 2026, then $199/month after, and the highest doses of Wegovy^® pill will be available for $299. Commercially insured patients pay as little as $25/month with the Wegovy^® savings offer.